Background. Pediatric pheochromocytomas and paragangliomas are rare with limited data on the optimal management approach. The aim of this study was to determine the role of genetic testing and imaging to detect extra-adrenal and/or metastatic tumors in pediatric pheochromocytomas and paragangliomas. Methods. We performed a retrospective study of 55 patients diagnosed at #21 years of age with pheochromocytomas and paragangliomas with analysis of data on genetic testing and multimodal imaging. Results. Eighty percent of patients (n = 44/55) had a germline mutation. The majority were found to have either VHL (38%) or SDHB (25%) mutation. Pheochromocytoma was present in 67% (n = 37/ 55) of patients and was bilateral in 51% (n = 19/37). The majority of patients with bilateral pheochromocytomas had VHL (79%). Abdominal paragangliomas was present in 22% (n = 12/55), head and neck paragangliomas in 11% (n = 6/55), and thoracic paragangliomas in 2 of 55 patients. For paragangliomas, SDHx accounted for 72% (n = 13/18) of mutations. The rate of malignancy was 16% (n = 9/55), 56% of whom had SDHB mutations. In two-thirds of patients, functional imaging identified either extra-adrenal paragangliomas and/or metastatic disease. Conclusion. The majority of pediatric patients with pheochromocytomas and paragangliomas have detectable germline mutations. Therefore, we suggest strongly that all pediatric patients with pheochromocytomas and paragangliomas undergo genetic testing and imaging to detect extra-adrenal paragangliomas and metastatic disease to guide treatment and follow-up. (Surgery 2017;161:220-7.) 
PHEOCHROMOCYTOMAS (PC) and paragangliomas (PGL) are rare neoplasms in the pediatric population that arise from the neural crest-derived chromaffin cells of the adrenal medulla and extra-adrenal ganglion. The incidence of PC/ PGL in the pediatric population is 0.2-0.3 cases per million persons. PC and the majority of abdominal PGL of sympathetic ganglia origin are functionally active with hypersecretion of catecholamines and their metabolites. Signs and symptoms of catecholamine excess include hypertension, headaches, and/or palpitations. PGLs of the head and neck are derived from parasympathetic ganglia and are commonly nonfunctioning neoplasms. 1 More than 14 germline and somatic mutations have been identified in association with PC/PGLs. 2 Common susceptibility genes for PC/PGLs include germline mutations in VHL, SDHx (SDHB and SDHD), RET, and NF1. Previous studies have identified that mutations in these genes may be present in up to 70% of individuals <18 years old who have PC/PGL. 3, 4 In the pediatric population, about one-third of patients with PC/PGL present with bilateral adrenal PC, of whom 18-22% have extra-adrenal PGL. 5, 6 The rate of malignancy reported has varied from 12-56%. 7 The rate of malignancy also varies depending on the presence of the specific germline mutation. For example, King et al 8 described metastatic PC/PGL associated with SDHB germline mutations in 72% of patients. A recent practice guideline from the Endocrine Society recommended considering genetic testing in all patients with PC/PGLs, although the clinical utility may be limited in individuals with unilateral PC, no family history, and no evidence of metastatic disease. In addition, computed tomography (CT) was recommended as first-line imaging for a new diagnosis of PC/PGL and functional imaging to evaluate for metastatic disease. 9 The aim of this study was to determine the role of genetic testing and imaging to detect extraadrenal and/or metastatic tumors in all pediatric patients with PC/PGLs.
METHODS AND MATERIALS
We conducted a retrospective analysis in pediatric patients (#21 years of age at diagnosis) with PC/PGLs. All patients were enrolled in clinical protocols (NCT00004847, NCT00062166, and NCT01005654) at the National Institutes of Health Clinical Center after written informed consent was obtained from the patient or their guardians. The studies were approved by the institutional review boards of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Cancer Institute.
Inclusion criteria for the current study included patients #21 years of age with biochemical, histologic, and/or imaging evidence of PC/ PGLs. Demographic data, including age at diagnosis, clinical presentation, family history, biochemical data, imaging, and pathology results were obtained from the electronic medical and radiology records. Biochemical data included plasma free metanephrine and normetanephrine, 24-hour urine fractionated metanephrine and normetanephrine, total 24-hour urine metanephrine, and plasma and 24-hour urine dopamine. Imaging studies included contrastenhanced anatomic CT imaging and/or magnetic resonance imaging (MRI) and at least one functional imaging modality: 18 Tumors were classified as solitary or multiple, PC laterality (unilateral or bilateral), bilateral at initial presentation (synchronous) or developing a contralateral PC after initial presentation (metachronous), recurrence, defined as tumor recurrence at a previously resected site or developing a new primary at a different anatomic location that was not metastatic disease. Recurrent lesions were active biochemically and/or patients were symptomatic. Primary tumor location was defined as adrenal or extra-adrenal abdominal, head and neck, or thoracic. Tumors were classified as benign or malignant based on metastasis to lymph nodes or distant sites where chromaffin cells are not present.
Genetic testing was performed in a laboratory certified by the Clinical Laboratory Improvement Amendments for PC/PGL susceptibility genes (VHL, RET, SDH A-D, NF1, and MAX). Time to recurrence was defined as presentation of new lesion(s) requiring operative intervention in X months from the last operative intervention. The results of CT and/or MRI and $1 functional imaging modality ( 
RESULTS
Genetic findings and rate of extra-adrenal and metastatic PC/PGLs. Fifty-five pediatric patients with PC/PGLs were included with a mean age at diagnosis of 13.6 ± 5.1 years. The clinical and genetic features of the study cohort are summarized in Table I . The Figure summarizes the frequency of distribution of PC/PGLs by age category and the germline mutation status. Genetic testing revealed that 80% of patients had a germline mutation in a known susceptibility gene: VHL 38%, SDHB 25.4%, SDHD 7.2%, RET 5.4%, SDHA 1.8%, NF1 1.8%, and MAX 1.8%. In 20% (n = 11/55) of patients, there was no known germline mutation identified.
In the entire cohort, 40% (n = 22/55) of patients had a family history; of those with a family history, all had a germline mutation. Of patients without a family history, 67% had a germline mutation (n = 22/33), VHL (n = 5/22), RET (n = 3/22), SDHB (n = 9/22), SDHD (n = 3/22), SDHA (n = 1/ 22), and NF1 (n = 1/22).
At initial presentation, PC was present in 67% (n = 37/55) of patients and 23% (n = 8/37) presented with bilateral synchronous PCs. Six of the patients with bilateral synchronous PC were found to have a VHL germline mutation, while in the remaining 2 patients, one had a germline SDHD and one had no known germline mutation. Eight percent (n = 3/37) of patients with PC presented with metastatic disease. Solitary PC with no family history or evidence of metastatic disease was present in 35% (n = 13/37) of patients. Of these patients, 62% (n = 8/13) had a germline mutation. VHL and RET were the most common mutations in patients with a solitary PC and no family history, each with 38% (n = 3/8). Thirty percent (n = 11/37) of patients with PCs developed metachronous, contralateral PCs over a span of 1.3 to 10 years (mean 2.7 ± 1.1 years).
Ultimately, 51% (n = 19/37) of pediatric patients had either bilateral synchronous or metachronous PCs. The majority of these patients (15/19) were found to have a VHL germline mutation (Table II) . Six patients with VHL and PC developed recurrences; 4 recurrences were a new primary at an extra-adrenal location (3 abdominal and 1 thoracic PGL), and 2 were in the remnant adrenal gland after partial adrenalectomy. Recurrence occurred over a span of 6 months to 16 years (mean 8.1 ± 6.2 years). The patient who recurred within 6 months had positive margins at the initial operation.
Eighteen patients at initial presentation had PGL. Extra-adrenal abdominal PGLs were present in 22% (n = 12/55). Six patients presented with a head and neck PGL. Two patients with previous PC/PGL resections presented with thoracic PGLs during follow-up. SDHx germline mutations were identified in 72% (n = 13/18) of patients with PGLs (SDHB 56%, n = 10/18; SDHD 17%, n = 3/ 18). In the remaining 5 patients, 1 had a VHL mutation and 4 had no germline mutation identified. Seventy-two percent (n = 13/18) of patients presenting with extra-adrenal and extra-abdominal PGLs had no family history.
The rate of malignancy was 16% (n = 9/55). Five patients had SDHB germline mutations, 1 patient had an SDHA germline mutation, and 3 had no known germline mutation. Three of these 9 patients presented initially with a PC, 4 with extraadrenal abdominal PGLs, and 2 with head and neck PGLs. Five of nine patients had skeletal metastasis; 3 patients had SDHB mutations. Of the remaining 2 patients, 1 had an SDHA mutation and 1 had no known mutation. The other 4 patients had evidence of metastasis based on pathology (2 had germline SDHB mutations).
Results of imaging. Imaging studies included anatomic imaging with contrast-enhanced CT and/or MRI and functional imaging with $1 of the following modalities: 18 Ga-DOTATATE PET/CT. Preoperative imaging studies were analyzed in the detection of PC/PGL based on histologically confirmed PC/PGLs of patients who had an operative intervention at our institution (Tables III and IV) . CT identified all PC and extra-abdominal PGLs but had only a 68% detection rate for abdominal PGLs. MRI had a detection rate of 93% for PC, 74% for abdominal PGLs, and 100% for extra-abdominal PGLs.
18 F-FDG PET/CT identified all extra-abdominal disease and had a greater detection rate for extra-adrenal PGLs compared with all other imaging modalities (Table IV) . 18 F-FDG PET/CT detected more skeletal metastasis when compared with I-123 MIBG. Five of 9 (55%) patients with malignant PC/PGL were found to have skeletal metastases by imaging. 18 F-FDG PET/CT identified skeletal metastases in all 5 patients. Two of the 5 patients with increased focal skeletal avidity on Ga-DO-TATATE PET/CT) was less in comparison to 18 F-FDG PET/CT and I-123 MIBG; however, all modalities identified a subset of known PC and PGL lesions.
DISCUSSION
PC/PGL in the pediatric population is rare. In this study, 80% of pediatric patients with PC/PGL were found to have a germline mutation in a known susceptibility gene. Of patients who had no family history, 66% had a germline mutation. Solitary PC with no family history or evidence of metastatic disease was present in 35% (n = 13/37) of patients with pheochromocytoma. Of those patients, 62% (n = 8/13) had a germline mutation, with VHL and RET mutations in 3 patients each and SDHx in the remaining 2.
18 F-FDG PET/CT detected more extra-adrenal tumors compared with all other imaging modalities. 18 F-FDG PET/CT had a comparable number of scans performed to I-123 MIBG and was superior when compared with I-123 MIBG for detecting extraadrenal PGL and skeletal metastasis. A small number of other functional studies were performed ( 18 F-FDOPA, 18 F-FDA PET/CT), which also detected skeletal metastasis.
A recent practice guideline from the Endocrine Society recommended considering genetic testing in patients with PC/PGL, but there were no specific recommendations for the pediatric population. In addition, the guideline also stated it may not be necessary to perform genetic testing in individuals with solitary PC or in those who do not have a family history or evidence of metastatic disease. 9 Our data in the pediatric population, which is defined as individuals <21 years old in this study, support the recommendation that all patients presenting with a PC/PGL should undergo genetic testing, including patients who present with a solitary PC and no family history or evidence of metastasis; approximately two-thirds of patients with a solitary PC with no family history or evidence of metastatic disease had a germline mutation. This finding underscores the importance of genetic testing in the pediatric population regardless of findings of a solitary PC or the lack of family history because of the implications for follow-up.
A comprehensive family history for PC/PGL and clinical manifestations (multiple endocrine neoplasia type 2 [MEN 2] and neurofibromatosis type 1) are indispensable when evaluating for which genetic test to perform. For patients without a family history, sequential genetic testing based on biochemical profile of catecholamine excess, age at presentation, tumor site, and tumor multiplicity and laterality have been proposed previously. 9, 10 We believe our data support testing for all known susceptibility genes given the high rate of carrier status identified in the pediatric population. Of the many susceptibility genes, VHL germline mutations have been described as the most common in pediatric PC/PGL, with patients as young as 5 years of age developing PC. 11 SDHB is the most common genetic mutation in PGL 3 and should be investigated in all individuals presenting with abdominal PGL and metastatic disease. Head and neck PGLs are associated frequently with SDHD mutations. 12 Head and neck PGLs have a low rate of metastatic disease, although this depends on the location of the neoplasm (eg, the rate of metastatic disease is only about 2% for carotid body PGL compared with 10% for vagal PGL). 13 In our cohort, one-third of patients with head and neck PGLs had metastatic disease diagnosed on functional imaging alone. Patients with MEN2 caused by a mutation in the RET proto-oncogene present or develop PC in 50% of cases.
14 Rarely, patients with neurofibromatosis type 1 present with a PC (1-5.7% of patients). This syndrome is caused by a mutation in the neurofibromatosis type 1 tumor suppressor gene 15 and is diagnosed commonly based on clinical criteria, which include the presence of $6 caf e-au-lait spots, $2 neurofibromas, and the presence of axillary or inguinal freckles. 16, 17 The myc-associated factor X (MAX) mutation was characterized recently. 18 This gene encodes proteins that are part of a family of transcription factors. A recent analysis of a large cohort of patients with PC/PGL were evaluated for MAX mutations but only about 1% were positive for the mutation. 19 Our study results showed a high rate of germline mutations in PC/PGL susceptibility genes in pediatric patients with PC/PGL are consistent with most studies. Hammond et al 20 identified germline mutations in all 7 patients with PC/PGL. Other investigators have also found a high rate of germline mutations, up to 70 %, in patients under the age of 18 years. 3, 4, 21 Our data suggest that all pediatric patients under the age of 21 years presenting with a PC/ PGL should have genetic testing performed for common susceptibility genes. This recommendation is also supported by the fact that 60% of the pediatric patients did not have a family history. One important factor used previously to support selective, sequential susceptibility gene testing for PC/PGL was the cost of genetic testing; however, with advances in next-generation sequencing allowing for simultaneous testing for mutations/ deletions in multiple susceptibility genes, such an approach could be cost-effective in pediatric patients with PC/PGL.
Contrast-enhanced CT is recommended as the first-line imaging modality for evaluation of PC/ PGL with a reported sensitivity of 88-100%, while MRI has been recommended for detection of head and neck PGL and 18 F-FDG PET/CT for metastatic disease. 9, 22 Our results support previously described findings that found 18 F-FDG PET/CT had greater sensitivity in comparison to I-123 MIBG for detecting metastatic lesions, specifically skeletal metastasis 22 as well as recurrent disease. 23 Functional imaging identified additional sites of disease not identified on anatomic imaging, specifically skeletal metastasis. Therefore, we maintain that it is necessary to have both anatomic and functional imaging when evaluating all pediatric patients who present with PC/PGL.
One of the main limitations of the current study is that our institution is a tertiary referral center and thus has a selection bias. Nevertheless, individuals with no family history, solitary neoplasms, or only symptoms and/or biochemical evidence of a PC/PGL without localization are also evaluated at our institution. Indeed, 60% of our study cohort had no family history and 75% had a solitary neoplasm at presentation, suggesting our findings would be applicable to the pediatric population with PC/PGL. The number of patients in the cohort is small, but pediatric PC/PGL is rare. Only a limited number of functional imaging MIBG, and therefore we can make no definitive conclusions about the specific functional imaging study that is best for detecting extraadrenal or metastatic disease.
In conclusion, we found that pediatric patients with PC/PGL have a high rate of germline mutations despite a lack of family history. Given these findings, pediatric patients with PC/PGL would benefit from genetic screening for all known susceptibility genes. Furthermore, these patients require multimodal imaging, including anatomic and functional imaging, to detect all disease sites for appropriate selection of treatment, follow-up, and family counseling.
Dr Nancy Perrier (Houston, TX): Will you tell us how this decision affected your operative plan? I think most of us in the audience agree with you in practice with doing genetic testing preoperatively on these patients. But in the 28 patients who had a solitary lesion, you told us that within 2 and a half years, up to 11, I think you said, went on to develop contralateral disease. Does that affect your plan, or knowing and looking at these data now, do you think more about cortical sparing adrenalectomy at the time of initial operation for the pheochromocytoma? And does the mutation status affect your decision based on weighing the risk/benefit of malignancy versus recurrence?
Dr Bruna Babic: Thank you for that question and excellent point. It absolutely did, especially the majority of those patients did have a VHL mutation, so certainly made us very acute in terms of follow-up. Again, this is a retrospective analysis, but we are fortunate to have the NIH as part of the protocol for the natural history they return to us annually. So, yes, it is important to continue in terms of imaging and certainly to do a cortical sparing adrenalectomy in those patients, as they might go on to develop contralateral disease.
Dr Nancy Perrier (Houston, TX): So have you changed your practice? Do you do cortical sparing on VHLs in children at the initial operation?
Dr Bruna Babic: Again, this is retrospective analysis, but the majority of these patients did get partial adrenalectomies, cortical sparing adrenalectomies.
Dr Jennifer E. Rosen (Washington, DC): Do you do the genetic testing prior to operating on these children?
Dr Bruna Babic: So these patients did have genetic analysis prior to their operative intervention.
Dr Jennifer E. Rosen (Washington, DC): And it did alter your surgical plan and your decision-making regarding what imaging to do? Dr Bruna Babic: Yes, it did. Dr Quan-Yang Duh (San Francisco, CA): I have a comment and a question. The comment is actually the Endocrine Society guidelines actually suggest that everybody with pheochromocytoma and paraganglioma get genetic counseling and potential testing, not just the pediatric patients. So I think what you are emphasizing is to get the mutational analysis before the operation. Do I hear that correct?
Dr Bruna Babic: Yes, absolutely. Certainly, what we are recommending is that even with the young individuals who present with a solitary tumor and no family history, just the fact that they were presenting at such a young age clearly makes us more acute to the fact that they may have a germline mutation, and everybody should undergo testing prior to intervention.
Dr Quan-Yang Duh (San Francisco, CA): So if you extend the rationale, wouldn't you want to do that for your adult patients, also? The risk is smaller, but it is still real.
Dr Bruna Babic: No, that is an excellent point, and I certainly think to that effect we need to look at those data as well.
Dr Douglas Evans (Milwaukee, WI): I agree that was just tremendous data. In your RET positive patients, I assume they did not have extra-adrenal pheo or paraganglioma. Then how about the VHL patients?
Dr Bruna Babic: We actually did have one patient who initially presented with a paraganglioma. The majority did present with pheochromocytoma.
Dr Douglas Evans (Milwaukee, WI): So if you have an isolated adrenal pheo, do you really need a PET in that patient?
Dr Bruna Babic: We do feel with our data that we have shown that you do.
Dr Douglas Evans (Milwaukee, WI): How? If you have an isolated adrenal pheo, with your CT or MRI---I am just trying to understand this---you are going to get genetic testing anyway before you operate on that patient. The likelihood would be that it would be a de novo mutation of RET or VHL in the absence of a family history, right? Dr Bruna Babic: True. Dr Jennifer E. Rosen (Washington, DC): So I have a follow-up question to that. Did you see any concordance between the genetic testing and the positivity in imaging or finding additional association? Did you find any association between the genetic testing and what particular PET scan you were going to get?
Dr Bruna Babic: What we certainly did find was our FDG-PET was the most useful. Again, there are additional research studies that are being done at the NIH, and we cannot draw definitive conclusions, but in comparison to MIBG, we found that FDG-PET was the most useful.
Dr Jennifer E. Rosen (Washington, DC): So, if I were to have a patient seen by you who is 13 years old with no known family history, they likely have already had a CT scan, chances are, what would be next? You would be ordering genetic testing?
Dr Bruna Babic: Genetic testing as well. We would recommend an FDG-PET.
